A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

NCT06267274 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Open-angle Glaucoma
Ocular Hypertension

Interventions

DRUG: Bimatoprost Ophthalmic Solution, 0.01%
DRUG: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%

Sponsor

Amneal Pharmaceuticals, LLC

Collaborators

[object Object]
[object Object]